Abstract: The present invention is a dentinal drug delivery composition composed of cationic and/or neutral porous particles containing an effective amount of a therapeutic agent and a method for using the same to provide a dental treatment.
Type:
Application
Filed:
November 23, 2010
Publication date:
December 27, 2012
Applicant:
University of Medicine and Dentistry of New Jersey
Abstract: Disclosed herein are nucleic acid sequences that encode novel polypeptides. In particular, the present invention provides nucleic acid molecules that include optimization features that enhance the expression and/or recovery and/or activity of encoded polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
Type:
Application
Filed:
June 19, 2012
Publication date:
December 6, 2012
Applicant:
UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
Inventors:
Jianjie Ma, Noah Weisleder, Chuanxi Cai
Abstract: A tissue, such as an amniotic or chorionic membrane, harvesting device that integrates a system facilitating subsequent storage of tissue samples. The device cuts a sample of the target tissue and automatically deposits the sample in a storage vessel. A method of collecting and storing a sample from a target tissue using a tissue harvesting device. A kit for collecting and storing samples of the target tissue.
Type:
Grant
Filed:
December 10, 2008
Date of Patent:
November 27, 2012
Assignee:
The University of Medicine and Dentistry of New Jersey
Abstract: The present invention is a population of breast cancer cells with preference for establishing dormancy in bone marrow. The breast cancer cells have characteristics of stem cells and express high levels of Oct4, designated Oct4hi, but are also not dependent on stem cell gene status. The Oct4hi cells exhibit functional gap junction intercellular communication with bone marrow stroma, indicating that these cells can establish dormancy and remain resistant to chemotherapy. Also provided by the present invention are a biomarker for metastatic breast cancer, a method for diagnosis and prognosis of breast cancer, and a method for identifying treatments that target dormant metastatic cells.
Type:
Application
Filed:
May 17, 2012
Publication date:
November 22, 2012
Applicant:
University of Medicine and Dentistry of New Jersey
Inventors:
Pranela Rameshwar, Lillian F. Pliner, Margarette Bryan
Abstract: A process for producing a small-sized, lipid-based cochleates. Cochleates are derived from liposomes which are suspended in an aqueous two-phase polymer solution, enabling the differential partitioning of polar molecule based-structures by phase separation. The liposome-containing two-phase polymer solution, treated with positively charged molecules such as Ca2+ or Zn2+, forms a cochleate precipitate of a particle size less than one micron. The process may be used to produce cochleates containing biologically relevant molecules.
Type:
Application
Filed:
April 6, 2012
Publication date:
November 22, 2012
Applicants:
University of Medicine and Dentistry of New Jersey, BioDelivery Sciences International, Inc.
Inventors:
Leila Zarif, Tuo Jin, Ignacio Segarra, Raphael J. Mannino
Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as doxorubicin (DOX) are introduced, which are equipotent to anticancer agents used in free form but exhibit significantly reduced cardiotoxicity and almost no adverse effects on normal bone marrow-derived mesenchymal stromal cells that do not express matriptase. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.
Type:
Application
Filed:
November 18, 2010
Publication date:
November 22, 2012
Applicant:
UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
Inventors:
Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
Abstract: A method for treating a degenerative or traumatic injury to a nerve tissue or the brain by administering at or near the injury site a composition containing adherent bone marrow stem cells suspended in a pharmaceutically acceptable liquid in an amount effective to elicit axonal regeneration or re-myelination at the site of injury.
Type:
Application
Filed:
October 16, 2009
Publication date:
November 1, 2012
Applicant:
UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
Abstract: This invention concerns compositions and methods of treating or diagnosing inflammatory disorders and other disorders, as well as compositions and methods of treating HIV.
Type:
Application
Filed:
April 13, 2012
Publication date:
October 18, 2012
Applicant:
UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
Abstract: The present invention relates generally to dental diseases, caries and periodontal disease. More specifically, the invention relates to Lactoferrin and Statherin fusion proteins (STAT-LF) along with therapeutic, diagnostic and research uses for these polypeptides. The present invention also provides methods of treating dental diseases, caries and periodontal disease.
Type:
Application
Filed:
February 15, 2012
Publication date:
October 18, 2012
Applicant:
UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
Abstract: Three unique subtypes of N-hydroxyamides and N-hydroxycarbamates containing both the vanilloid moiety (4-hydroxy-3-methoxybenzyl) and a lipophilic aliphatic moiety. Also disclosed are direct syntheses of these vanilloid fatty hydroxamates. The compounds possess inhibitory activity against the enzymes fatty acid amide hydrolase (FAAH) and matrix metallo-proteinase 9 (MMP-9). In addition, these substances bind to the calcium channel protein TRPV1 and inhibit vesicant-induced inflammation in skin and cornea. The compounds have utility in treating topical or systemic inflammatory processes in the skin and/or eye.
Type:
Application
Filed:
March 16, 2012
Publication date:
October 4, 2012
Applicants:
University of Medicine and Dentistry of New Jersey, Lehigh University, Rutgers, The State University of New Jersey
Inventors:
Jeffrey D. Laskin, Ned D. Heindel, Carl Jeffrey Lacey, Abhilash N. Pillai, Marion Gordon, Diane E. Heck
Abstract: An assembly of a pulmonary venting catheter and a pacing wire disposed therethrough whereby the pacing wire is extended from the distal end of the catheter tube during pacing mode, eliminating the need for exchanging the venting catheter with a pacing catheter to begin pacing after venting. The pacing wire includes a flexible distal end for a first conductor to conductively engage heart tissue after the pacing wire is extended from the catheter distal end; a second conductor, also exposed outside the catheter distal end, completes the circuit. The pacing wire is lockable in unextended and extended positions at the proximal end portion of the assembly. A method for venting and pacing a patient's heart during cardiac surgery is described, which includes retracting the catheter distal end from the pulmonary artery after venting mode, into the right ventricle during pacing mode, whereafter the pacing wire is extended for pacing.
Type:
Application
Filed:
April 2, 2012
Publication date:
October 4, 2012
Applicant:
UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
Abstract: The present invention is a method for determining the thermal stability of a collagen peptide, collagen-like peptide or triple-helix construct with the repeating peptide unit Gly-Xaa1-Xaa2. The instant method accounts for the destabilizing effect of peptide repeats which do not conform to the highly stable Gly-Pro-Hyp peptide and for the interaction between triplets. The instant method finds use in mutant analysis of collagen peptides, collagen-like peptides or triple-helix constructs and engineering of collagen peptides, collagen-like peptides or triple-helix constructs.
Type:
Grant
Filed:
February 3, 2006
Date of Patent:
October 2, 2012
Assignee:
University of Medicine and Dentistry of New Jersey
Inventors:
Anton V. Persikov, John A. M. Ramshaw, Barbara M. Brodsky
Abstract: The present invention relates to a method for treating a patient having disorder characterized by a deficient amount of functional CLN2 protein in the affected cells, which comprises administering to the patient an amount of CLN2 protein effective to reduce or eliminate the symptoms caused by the deficiency in CLN2 protein.
Type:
Grant
Filed:
August 29, 2011
Date of Patent:
October 2, 2012
Assignee:
University of Medicine and Dentistry of New Jersey
Abstract: The invention relates to pharmaceutical compositions comprising trophic factors, methods to decrease the degeneration of a retina, methods of treating ocular degenerative diseases and methods to select cells for transplantation.
Type:
Application
Filed:
March 14, 2012
Publication date:
September 20, 2012
Applicant:
UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
Inventors:
Anton Kolomeyer, Ilene Sugino, Marco Zarbin
Abstract: The invention provides compounds of formula (I) wherein u, d, v, m, n, R1, W, X, Y, and Z have any values defined herein, as well as salts thereof. The compounds have activity as anti-proliferative agents.
Type:
Application
Filed:
November 5, 2010
Publication date:
September 20, 2012
Applicants:
UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY, RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Inventors:
Edmond J. LaVoie, Joseph E. Rice, Suzanne G. Rzuczek, Daniel S. Pilch
Abstract: The invention relates to compositions and methods for diagnosing and treating cardiac conditions and neurodegenerative diseases using antibodies which specifically recognize and bind to the adenylyl cyclase 5 isoform in the heart and brain. These antibodies demonstrate high specificity to the AC5 isoform and do not cross react to any other AC5 isoform. The invention further relates to methods of delivery of drugs to the site of injured tissue using the antibodies of the present invention.
Type:
Grant
Filed:
May 26, 2005
Date of Patent:
September 11, 2012
Assignee:
University of Medicine and Dentistry of New Jersey
Inventors:
Stephen F. Vatner, Dorothy E. Vatner, Junichi Sadoshima, Jayashree Pain
Abstract: Polysaccharide-containing extracts isolated from a host cell containing nucleotide sequences encoding genes pamA, pamB and pamC, wherein the extract is capable of inhibiting biofilm formation produced by gram-negative bacteria, gram-positive bacteria and fungi, and methods to inhibit biofilm formation or remove biofilms that have already formed.
Type:
Application
Filed:
January 26, 2012
Publication date:
September 6, 2012
Applicant:
University of Medicine and Dentistry of New Jersey
Inventors:
Jeffrey B. Kaplan, Nataliya V. Balashova, Scott C. Kachlany, Evguenii Vinogradov
Abstract: The present invention relates to compositions and methods of treating, inhibiting, or controlling HIV infection.
Type:
Application
Filed:
October 11, 2011
Publication date:
September 6, 2012
Applicant:
UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
Inventors:
Michael B. Mathews, Hartmut M. Hanauske-Abel, Tsafi Pe'ery, Mainul Hoque, Paul Palumbo, Deepti Saxena, Darlene D'Alliessi-Gandolfi, Myung-Hee Park